IMMATICS NV-
IMMATICS NV-
Share · NL0015285941 · IMTX · A2P72S (XNAS)
Overview Financial Indicators
5,97 USD
3,29 % 0,19 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 20:00

Current Prices from IMMATICS NV-

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
IMTX
USD
06.06.2025 20:00
5,97 USD
5,78 USD
+3,29 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 10,76 % 30,07 % 24,38 % -23,95 % -55,74 % -56,93 %

Company Profile for IMMATICS NV- Share

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Company Data

Name IMMATICS NV-
Company Immatics N.V.
Symbol IMTX
Website https://www.immatics.com
Primary Exchange XNAS NASDAQ
WKN A2P72S
ISIN NL0015285941
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Harpreet Singh Ph.D.
Market Capitalization 505 Mio
Country Germany
Currency USD
Employees 0,6 T
Address Paul-Ehrlich-Strasse 15, 72076 Tübingen
IPO Date 2018-12-12

ID Changes

Date From To
02.07.2020 ARYA IMTX

Ticker Symbols

Name Symbol
Frankfurt 4A3.F
NASDAQ IMTX

More Shares

Investors who IMMATICS NV- hold also have the following shares in their portfolio:
ALLIANZ AG
ALLIANZ AG Share
BASTEI LUEBBE AG
BASTEI LUEBBE AG Share
BIONTECH SE ADR
BIONTECH SE ADR Share
COCA-COLA CO
COCA-COLA CO Share
KRED.F.WIED.V.23/2025 DL
KRED.F.WIED.V.23/2025 DL Bond
MICROSOFT CORP
MICROSOFT CORP Share
Novo Nordisk (alt)
Novo Nordisk (alt) Share
NVIDIA CORP
NVIDIA CORP Share
OATLY GROUP AB - AMERICAN DEPOSITARY SHARES
OATLY GROUP AB - AMERICAN DEPOSITARY SHARES Depository Receipt
PEPSICO INC
PEPSICO INC Share
SIEMENS ENERGY AG
SIEMENS ENERGY AG Share
SIEMENS HEALTHINEER AG
SIEMENS HEALTHINEER AG Share
VERBIO VEREINIGTE BIOENERGIE AG
VERBIO VEREINIGTE BIOENERGIE AG Share
Western Midstream Partners, LP Common Units Representing Limited Partner Interests
Western Midstream Partners, LP Common Units Representing Limited Partner Interests Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025